Eli Lilly secures 1.5 billion dollar deal for Calytrix Bio to expand blood cancer pipeline
Eli Lilly has agreed to a deal worth up to $1.5 billion to acquire Calytrix Bio, gaining access to a preclinical antibody designed to target rare blood cancers. This move builds on Lilly's ongoing investments in treatments for myelofibrosis and related conditions.

Original image temporarily unavailable
Eli Lilly is further expanding its footprint in the treatment of rare blood cancers by striking a deal worth up to $1.5 billion for Calytrix Bio, a biotech founded by J.P. Morgan's life sciences venture capital arm. The acquisition centers on a preclinical biparatopic antibody designed to target mutant calreticulin, which drives conditions like essential thrombocythemia and myelofibrosis. Unlike current therapies that primarily manage symptoms, this approach aims to provide disease-modifying activity. Citi analysts noted that the asset strategically complements Lilly's existing pipeline assets, though they cautioned that the program is still in the preclinical stage and faces a high safety bar. This transaction caps off a busy year of multibillion-dollar acquisitions and licensing agreements for Lilly, fueled largely by the strong sales of its GLP-1 drugs.
View selection rationale
Importance 53/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.